GAMMA Investing LLC Purchases 128,852 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

GAMMA Investing LLC raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 6,875.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,726 shares of the biotechnology company's stock after buying an additional 128,852 shares during the period. GAMMA Investing LLC owned about 0.06% of ADMA Biologics worth $2,594,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. B Group Inc. acquired a new stake in ADMA Biologics during the 4th quarter valued at approximately $39,231,000. Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics during the 4th quarter valued at about $19,076,000. Arrowstreet Capital Limited Partnership lifted its holdings in ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock valued at $47,380,000 after acquiring an additional 1,013,456 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director now owns 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director now directly owns 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,000 shares of company stock valued at $814,936 in the last quarter. Insiders own 3.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Stock Down 3.7%

Shares of ADMA traded down $0.79 during midday trading on Friday, reaching $20.81. 2,765,499 shares of the company were exchanged, compared to its average volume of 3,666,750. The company has a market cap of $4.97 billion, a price-to-earnings ratio of 74.32 and a beta of 0.47. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1-year low of $10.21 and a 1-year high of $25.67. The stock has a 50-day moving average price of $20.88 and a 200-day moving average price of $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the company posted $0.08 EPS. The business's revenue for the quarter was up 40.2% compared to the same quarter last year. Research analysts expect that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.